Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 9, 2012

Primary Completion Date

April 1, 2013

Study Completion Date

April 1, 2013

Conditions

Hepatic ImpairmentHealthy

Interventions

DRUG

SSP-004184

All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1

Trial Locations (2)

Orlando Clinical Research Center (OCRC), Orlando

Clinical Pharmacology of Miami, Miami